NanosanguisS.A.
Research and experimental development in natural sciences and engineering
Overview
Nanosanguis is a biotechnology company focused on utilizing nanotechnology in medicine, specifically in the fields of transplantation and transfusion. It aims to increase the availability of organs for transplantation by developing innovative organ perfusion systems and a safe, effective blood substitute. The company also seeks to enhance organ preservation methods and expand the donor pool by utilizing kidneys from donors after circulatory death.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-01-29. Active
42 1090 1056 0000 0001 4863 9955
28 1950 0001 2006 0017 4959 0005- 12 1950 0001 2006 0017 4959 0002
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 19, 2017 | Commercial Companies Code notice | |
| Apr 19, 2016 | Commercial Companies Code notice |
Public aid
17 public aid cases recorded, with a total value of $9,945,966.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Aug 5, 2025 | Aid for research and development projects: industrial research | $3.9M$3,922,151 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Aug 5, 2025 | Aid for research and development projects: experimental development | $1.7M$1,686,318 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Apr 24, 2025 | Aid for research and development projects: industrial research | $507.0K$506,972 | Prezes Agencji Badań Medycznych |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $7,415,789.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-11-01 | NanOX 4 Kidney – nowej generacji płyn do perfuzji nerek na bazie syntetycznego nośnika tlenu | $5.6M$5,595,822 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2020-07-15 | Opracowanie znacząco ulepszonego urządzenia do normotermicznej perfuzji organów w dziedzinie transplantologii. | $82,825$82,825 | Program Operacyjny Inteligentny Rozwój | |
| 2016-10-01 | OrganFarm- system do długoterminowego przechowywania organów ex vivo | $1.3M$1,311,841 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the President of the Management Board is authorized to make declarations of will on behalf of the company and to represent the company. If a multi-member management board is appointed, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to perform legal acts and make declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Tomasz Adam Ciach (61)  | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Przemysław Daniel Mazurek (50) | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Piotr Paweł Mierzejewski (62) | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| BiottsS.A. | $372,115.60 | biotts.com | ||
| MedisensonicS.A. | $362,572.63 | medisensonic.com | ||
| PolbionicaS.A. | $356,011.70 | polbionica.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Nantes - Systemy Nanotechnologiisp. z o.o. | $191,244.59 | nantes.com.pl | ||
| Nexbiosp. z o.o. | $186,582.40 | nexbio.pl | ||
| Nanoo Printerssp. z o.o. | $150,791.60 | nanooprinters.eu | ||
| Sfpesp. z o.o. | $72,850.26 | sfpe.co.pl | ||
| New Valuesp. z o.o. | $64,335.86 | new-value.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-09-16 | PKD change (Removed: 70.22.Z, 71.12.Z, 71.20.A, 71.20.B, 72.11.Z, 72.19.Z, 74.90.Z; Added: 70.20.Z, 71.12.B, 71.20.C, 72.10.Z, 74.91) | |
| 2025-01-24 | Share capital change (3,888,560.00 PLN → 4,068,587.00 PLN) | |
| 2024-07-10 | Share capital change (3,788,560.00 PLN → 3,888,560.00 PLN) | |
| 2024-02-13 | Share capital change (3,343,560.00 PLN → 3,788,560.00 PLN) | |
| 2023-06-12 | Share capital change (1,278,756.00 PLN → 3,343,560.00 PLN) |
FAQ
Last updated: 2026-07-17